Fig. 5. CD61+ TILs have enhanced antitumor effector phenotypes in NSCLC.
a, Expression of cytolytic molecules (granulysin, granzyme M, granzyme B), degranulation marker CD107a, chemokines (CCL5, XCL2) and cytokines (TNF, IFN-γ) between CD61+ and CD61− TILs, by representative flow cytometry plots of 1 patient (patient 7). b, Dot plots of the average MFI and frequency of cytolytic molecules, cytokines and chemokines, by flow cytometry. c, Dot plot showing the percentage of CD61+ TILs expressing granulysin and granzyme M following ex vivo αCD61 neutralizing antibody treatment or no treatment ex vivo. P value granulysin: 0.00021, P value granzyme M: 0.045. d, Line plot on the frequency of combinatorial effector signatures positive (IFN-γ+TNF+CCL5+XCL2+granzyme M+granzyme B+granulysin+) cells between CD61+ and CD61− TILs. P value: 0.00087. e, The frequency of CD61+CD103+CD8+ co-located cells or CD61−CD103+CD8+ co-located cells present within the tumor body, clustering around the tumor body, or further from the tumor body, by IHC. Data are presented as the median ± s.e.m. P value (within tumor islets): 0.0009, P value (further from islets): 0.00078. f, Line plot on the frequency of cells with tumor-reactive combinatorial markers expression (CD39+CD103+) between CD61+ and CD61− TILs. P value: 0.00074. c–f, ***P < 0.001, *P < 0.05; one-way ANOVA with Tukey’s multiple-comparison test (c and e) or two-tailed t-test with Wilcoxon adjustment (d and f). b–f, n = 19 patients. mAb, monoclonal antibody.